Kateryna Priadko

Dr. Kateryna Priadko

University of Campania "Luigi Vanvitelli" - Department of Mental, Physical Health and Preventive Medicine
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAntonietta Gerarda Gravina
Antonietta Gerarda Gravina
KPKateryna Priadko
Kateryna Priadko
PCPaola Ciamarra
Paola Ciamarra
LGlucia granata
lucia granata
AFAngela Facchiano
Angela Facchiano
MRMarco Romano
Marco Romano
Helicobacter Pylori (H. pylori) is a Gram-negative flagellated microorganism that has been extensively studied since its first isolation due to its widespread diffusion and association with numerous diseases. While the bacterium is proved to be a causative factor for a number of gastric diseases such as gastritis, gastric adenocarcinoma, and MALT-lymphoma, its role at other gastrointestinal levels and in other systems is being thoroughly studied. In this article, we reviewed the latest published clinical and laboratory studies that investigated associations of H. pylori with hematologic diseases such as Vitamin B12- and iron-deficiency anemia, primary immune thrombocytopenia, and with a number of dermatologic and ophthalmic diseases. In addition, the putative role of the bacterium in inflammatory bowel diseases, esophageal disorders, metabolic, diseases, neurologic diseases and allergy were outlined.

20 April 2020 in Helicobacter
Verified
Journal Article
Open access
PDF file
MRMarco Romano
Marco Romano
AGAntonietta Gerarda Gravina
Antonietta Gerarda Gravina
GNGerardo Nardone
Gerardo Nardone
AFAlessandro Federico
Alessandro Federico
MDMarcello Dallio
Marcello Dallio
RZRocco Maurizio Zagari
Rocco Maurizio Zagari
Background: Bismuth quadruple (BQT) and non‐bismuth quadruple (N‐BQT) therapies are the recommended first‐line treatments for Helicobacter (H.) pylori infection.Objective: To compare the efficacy of BQT and N‐BQT in clinical practice in an area with high clarithromycin resistance, choosing the regimen on the basis of previous exposure to clarithromycin.Methods: A total of 404 consecutive H pylori‐positive, naïve patients were enrolled. A total of 203 patients without previous exposure to clarithromycin received N‐BQT, 100 patients for 10 days and 103 for 14 days, whereas 201 with previous exposure to clarithromycin received 10‐day BQT. Efficacy and treatment‐related adverse events were assessed.Results and Conclusions: Eradication rates by intention‐to‐treat analysis were 88.2% for N‐BQT and 91.5% for BQT (P = .26); per‐protocol analysis eradication rates were 91.2% and 95.8% for N‐BQT and BQT, respectively (P = .07). Eradication rates were significantly higher with 14‐day than 10‐day CT (P < .003). Almost all patients had a good compliance with both N‐BQT (95.6%) and BQT (95%). Adverse events occurred in 24.1% and 26.9% (P = .53) of patients in the N‐BQT and BQT group, respectively. In conclusion, clarithromycin‐containing non‐bismuth or bismuth quadruple therapy, based on the knowledge of previous clarithromycin exposure, is effective and safe even in an area of high prevalence of clarithromycin‐resistant H pylori strains.

27 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TMTamara Matysiak-Budnik
Tamara Matysiak-Budnik
KPKateryna Priadko
Kateryna Priadko
CBCéline Bossard
Céline Bossard
NCNicolas Chapelle
Nicolas Chapelle
ARAgnès Ruskoné-Fourmestraux
Agnès Ruskoné-Fourmestraux
Gastric mucosa-associated lymphoid tissue (MALT) lymphomas (GML) are non-Hodgkin lymphomas arising from the marginal zone of the lymphoid tissue of the stomach. They are usually induced by chronic infection with Helicobacter pylori (H. pylori); however, H. pylori-negative GML is of increasing incidence. The diagnosis of GML is based on histological examination of gastric biopsies, but the role of upper endoscopy is crucial since it is the first step in the diagnostic process and, with currently available novel endoscopic techniques, may even allow an in vivo diagnosis of GML per se. The treatment of GML, which is usually localized, always includes the eradication of H. pylori, which should be performed even in H. pylori-negative GML. In the case of GML persistence after eradication of the bacteria, low-dose radiotherapy may be proposed, while systemic treatments (immunochemotherapy) should be reserved for very rare disseminated cases. In GML patients, at diagnosis but even after complete remission, special attention must be paid to an increased risk of gastric adenocarcinoma, especially in the presence of associated gastric precancerous lesions (gastric atrophy and gastric intestinal metaplasia), which requires adequate endoscopic surveillance of these patients.

24 May 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
CSCostantino Sgamato
Costantino Sgamato
ARAlba Rocco
Alba Rocco
DCDebora Compare
Debora Compare
KPKateryna Priadko
Kateryna Priadko
MRMarco Romano
Marco Romano
GNGerardo Nardone
Gerardo Nardone
Gastric cancer (GC) still represents one of the leading causes of cancer-related mortality and is a major public health issue worldwide. Understanding the etiopathogenetic mechanisms behind GC development holds immense potential to revolutionize patients’ treatment and prognosis. Within the complex web of genetic predispositions and environmental factors, the connection between Helicobacter pylori (H. pylori) and gastric microbiota emerges as a focus of intense research investigation. According to the most recent hypotheses, H. pylori triggers inflammatory responses and molecular alterations in gastric mucosa, while non-Helicobacter microbiota modulates disease progression. In this review, we analyze the current state of the literature on the relationship between H. pylori and non-Helicobacter gastric microbiota in gastric carcinogenesis, highlighting the mechanisms by which microecological dysbiosis can contribute to the malignant transformation of the mucosa.

14 February 2024 in The Prostate
Verified
Journal Article
Closed access
LRLorenzo Romano
Lorenzo Romano
LNLuigi Napolitano
Luigi Napolitano
FCFelice Crocetto
Felice Crocetto
CSCarmine Sciorio
Carmine Sciorio
MSMarco De Sio
Marco De Sio
KPKateryna Priadko
Kateryna Priadko

5 May 2023 in Journal of Ultrasound
Verified
Journal Article
Open access
PDF file
ISIlario de Sio
Ilario de Sio
MDMirko D’oNofrio
Mirko D’oNofrio
PMPaoletta Mirk
Paoletta Mirk
MBMichele Bertolotto
Michele Bertolotto
KPKateryna Priadko
Kateryna Priadko
FAFabia Attili
Fabia Attili
Extrahepatic biliary tract and gallbladder neoplastic lesions are relatively rare and hence are often underrepresented in the general clinical recommendations for the routine use of ultrasound (US). Dictated by the necessity of updated summarized review of current literature to guide clinicians, this paper represents an updated position of the Italian Society of Ultrasound in Medicine and Biology (SIUMB) on the use of US and contrast-enhanced ultrasound (CEUS) in extrahepatic biliary tract and gallbladder neoplastic lesions such as extrahepatic cholangiocarcinoma, gallbladder adenocarcinoma, gallbladder adenomyomatosis, dense bile with polypoid-like appearance and gallbladder polyps.